Compare · HTFL vs SYK
HTFL vs SYK
Side-by-side comparison of Heartflow Inc. (HTFL) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HTFL and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 25.4x HTFL ($4.43B).
- Over the past year, HTFL is up 42.5% and SYK is down 21.3% - HTFL leads by 63.9 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 2 for HTFL).
- SYK has more recent analyst coverage (25 ratings vs 9 for HTFL).
- Company
- Heartflow Inc.
- Stryker Corporation
- Price
- $48.23-5.21%
- $294.69+0.46%
- Market cap
- $4.43B
- $112.48B
- 1M return
- -2.71%
- +5.16%
- 1Y return
- +42.52%
- -21.34%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 8
- Recent ratings
- 9
- 25
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest HTFL
- SEC Form 4 filed by Heartflow Inc.
- Chief Medical Officer Rogers Campbell exercised 13,179 shares at a strike of $7.94 and sold $987,052 worth of shares (19,682 units at $50.15) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 79,956 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $1,230,742 worth of Common Stock. (24,345 units at $50.55) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 155,183 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $1,751,611 worth of Common Stock. (34,975 units at $50.08) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 179,528 units (SEC Form 4)
- Chief Executive Officer Farquhar John C.M. sold $1,819,605 worth of shares (38,900 units at $46.78) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 321,914 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $332,212 worth of Common Stock. (6,640 units at $50.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 214,503 units (SEC Form 4)
- UBS resumed coverage on Heartflow with a new price target
- Chief Financial Officer Verghese Vikram sold $1,665,796 worth of Common Stock. (33,416 units at $49.85) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 221,143 units (SEC Form 4)
- Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
- Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)